[go: up one dir, main page]

CY1110329T1 - Πεγκυλιωμενη λιποσωμιακη δοξορουβικινη σε συνδυασμο με εκτεϊνασκιδινη 743 - Google Patents

Πεγκυλιωμενη λιποσωμιακη δοξορουβικινη σε συνδυασμο με εκτεϊνασκιδινη 743

Info

Publication number
CY1110329T1
CY1110329T1 CY20091100818T CY091100818T CY1110329T1 CY 1110329 T1 CY1110329 T1 CY 1110329T1 CY 20091100818 T CY20091100818 T CY 20091100818T CY 091100818 T CY091100818 T CY 091100818T CY 1110329 T1 CY1110329 T1 CY 1110329T1
Authority
CY
Cyprus
Prior art keywords
combination
ectein
succinin
pegylated liposomal
liposomal doxorubicin
Prior art date
Application number
CY20091100818T
Other languages
English (en)
Inventor
Erard Gilles
Lars-Axel Sternas
Ovid Trifan
De Velde Helgi Van
April Teitelbaum
Original Assignee
Pharma Mar S.A., Sociedad Unipersonal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36096124&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1110329(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharma Mar S.A., Sociedad Unipersonal filed Critical Pharma Mar S.A., Sociedad Unipersonal
Publication of CY1110329T1 publication Critical patent/CY1110329T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Μέθοδος αγωγής καρκίνου του ανθρώπινου σώματος που αποτελείται από χορήγηση αποτελεσματικής θεραπευτικής ποσότητας μορφή λιποσωμιακής πεγκυλίασης της ανθρακυκίνης Δοξορουβικίνης ("PLD") σε συνδυασμό με αποτελεσματική θεραπευτική ποσότητα ET-743.
CY20091100818T 2004-10-26 2009-08-03 Πεγκυλιωμενη λιποσωμιακη δοξορουβικινη σε συνδυασμο με εκτεϊνασκιδινη 743 CY1110329T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62216304P 2004-10-26 2004-10-26
EP05803151A EP1827500B1 (en) 2004-10-26 2005-10-26 Pegylated liposomal doxorubicin in combination with ecteinescidin 743

Publications (1)

Publication Number Publication Date
CY1110329T1 true CY1110329T1 (el) 2015-01-14

Family

ID=36096124

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100818T CY1110329T1 (el) 2004-10-26 2009-08-03 Πεγκυλιωμενη λιποσωμιακη δοξορουβικινη σε συνδυασμο με εκτεϊνασκιδινη 743

Country Status (26)

Country Link
US (1) US20090117176A1 (el)
EP (1) EP1827500B1 (el)
JP (2) JP4554684B2 (el)
KR (1) KR101287918B1 (el)
CN (1) CN101119750B (el)
AT (1) ATE430586T1 (el)
AU (1) AU2005298364B2 (el)
BR (1) BRPI0518250A2 (el)
CA (1) CA2582452C (el)
CY (1) CY1110329T1 (el)
DE (1) DE602005014380D1 (el)
DK (1) DK1827500T3 (el)
ES (1) ES2326825T3 (el)
HR (1) HRP20090345T1 (el)
IL (1) IL182352A (el)
MX (1) MX2007004744A (el)
NO (1) NO328958B1 (el)
NZ (1) NZ554765A (el)
PL (1) PL1827500T3 (el)
PT (1) PT1827500E (el)
RS (1) RS50822B (el)
RU (1) RU2359700C2 (el)
SI (1) SI1827500T1 (el)
UA (1) UA87877C2 (el)
WO (1) WO2006046080A2 (el)
ZA (1) ZA200703396B (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
KR100718946B1 (ko) * 2000-11-06 2007-05-16 파르마 마르, 에스.에이. 효과적인 항종양 치료
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
SI1689404T1 (sl) 2003-11-13 2009-02-28 Pharma Mar Sau Kombinacija et-743 s 5-fluorouracil pro zdravili za zdravljenje raka
CN1897949A (zh) * 2003-11-14 2007-01-17 马尔药品公司 包含使用et－743和紫杉醇来治疗癌症的联合疗法
NZ554761A (en) 2004-10-29 2010-01-29 Pharma Mar Sa Formulations comprising ecteinascidin and a disaccharide
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
US8444963B2 (en) 2006-06-19 2013-05-21 John Hopkins University Tumor specific delivery of therapeutic agents via liposomase
JP2011500046A (ja) * 2007-10-19 2011-01-06 ファルマ・マール・ソシエダード・アノニマ Ｅｔ−７４３治療のための予後分子マーカー
KR20190062485A (ko) 2016-09-27 2019-06-05 버텍스 파마슈티칼스 인코포레이티드 Dna-손상제 및 dna-pk 저해제의 조합을 사용한 암 치료 방법
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
RU2657835C1 (ru) * 2017-11-28 2018-06-15 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский технологический университет "МИСиС" Способ получения системы для доставки противоопухолевого препарата в клетки опухоли

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5089273A (en) * 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
DE3635711A1 (de) * 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) * 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
GB9508195D0 (en) * 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) * 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
DE69936845T2 (de) * 1998-04-06 2008-05-08 The Board Of Trustees Of The University Of Illinois, Urbana Halbsynthetische ectein-ascidine
US6124292A (en) * 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
AR035842A1 (es) * 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
US20020028237A1 (en) * 2000-04-20 2002-03-07 Colbern Gail T. Method for reducing toxicity of a cytotoxic agent
US7247892B2 (en) * 2000-04-24 2007-07-24 Taylor Geoff W Imaging array utilizing thyristor-based pixel elements
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
US7420051B2 (en) * 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
WO2002014554A2 (en) * 2000-08-11 2002-02-21 City Of Hope The anti-neoplastic agent et-743 inhibits trans activation by sxr
IL155297A0 (en) * 2000-10-31 2003-11-23 Pharma Mar Sa Kahalalide f formulation
KR100718946B1 (ko) * 2000-11-06 2007-05-16 파르마 마르, 에스.에이. 효과적인 항종양 치료
HRP20030801A2 (en) * 2001-03-06 2004-08-31 Bristol Myers Squibb Co Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin
US7387790B2 (en) * 2001-06-15 2008-06-17 Cornerstone Pharmaceuticals Pharmaceutical and diagnostic compositions containing nanoparticles useful for treating targeted tissues and cells
IL161430A0 (en) * 2001-10-19 2004-09-27 Pharma Mar Sa Pharmaceutical compositions containing ecteinascidin 743
US20040019027A1 (en) * 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
WO2004006755A2 (en) * 2002-07-16 2004-01-22 Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California Support bra for ultrasonic breast scanner
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
SI1689404T1 (sl) * 2003-11-13 2009-02-28 Pharma Mar Sau Kombinacija et-743 s 5-fluorouracil pro zdravili za zdravljenje raka
CN1897949A (zh) * 2003-11-14 2007-01-17 马尔药品公司 包含使用et－743和紫杉醇来治疗癌症的联合疗法
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
US20050129752A1 (en) * 2003-12-15 2005-06-16 Tty Biopharm Limited Company Use and manufacturing process for liposomal doxorubicin pharmaceutical composition
MX2007000360A (es) * 2004-07-09 2007-06-12 Pharma Mar Sa Marcadores moleculares de pronostico.
NZ554761A (en) * 2004-10-29 2010-01-29 Pharma Mar Sa Formulations comprising ecteinascidin and a disaccharide
WO2007062413A2 (en) * 2005-11-25 2007-05-31 University Of Medicine And Dentistry Of New Jersey Use of parp-1 inhibitors
US20080075772A1 (en) * 2006-04-13 2008-03-27 Lawrence Solomon Pharmaceutical compositions having novel scoring patterns and methods of using those compositions
WO2007134203A2 (en) * 2006-05-12 2007-11-22 Pharma Mar, S.A. Anticancer treatments with a combination of docetaxel and ecteinascidin

Also Published As

Publication number Publication date
DK1827500T3 (da) 2009-08-31
JP2009292850A (ja) 2009-12-17
US20090117176A1 (en) 2009-05-07
EP1827500B1 (en) 2009-05-06
SI1827500T1 (sl) 2009-10-31
RU2007119545A (ru) 2008-12-10
RS50822B (sr) 2010-08-31
KR20070108135A (ko) 2007-11-08
JP2008517991A (ja) 2008-05-29
NO328958B1 (no) 2010-06-28
JP4554684B2 (ja) 2010-09-29
IL182352A0 (en) 2007-07-24
HK1107766A1 (en) 2008-04-18
PT1827500E (pt) 2009-08-05
CA2582452A1 (en) 2006-05-04
WO2006046080A8 (en) 2007-07-12
AU2005298364B2 (en) 2009-03-26
ZA200703396B (en) 2008-11-26
UA87877C2 (en) 2009-08-25
MX2007004744A (es) 2007-10-23
DE602005014380D1 (de) 2009-06-18
CA2582452C (en) 2010-09-07
CN101119750B (zh) 2013-03-06
ATE430586T1 (de) 2009-05-15
CN101119750A (zh) 2008-02-06
NZ554765A (en) 2010-01-29
RU2359700C2 (ru) 2009-06-27
EP1827500A2 (en) 2007-09-05
HRP20090345T1 (en) 2009-08-31
KR101287918B1 (ko) 2013-07-19
WO2006046080A2 (en) 2006-05-04
WO2006046080A3 (en) 2006-10-19
AU2005298364A1 (en) 2006-05-04
NO20072543L (no) 2007-07-13
ES2326825T3 (es) 2009-10-20
PL1827500T3 (pl) 2009-09-30
IL182352A (en) 2016-07-31
BRPI0518250A2 (pt) 2008-11-11

Similar Documents

Publication Publication Date Title
CY1110329T1 (el) Πεγκυλιωμενη λιποσωμιακη δοξορουβικινη σε συνδυασμο με εκτεϊνασκιδινη 743
DE60138611D1 (de) Synergistische kombinationstherapie zur krebsbehandlung
FR2869231B1 (fr) Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine
AU4550801A (en) Herbal composition phy906 and its use in chemotheraphy
MXPA05012421A (es) Tratamiento sinergistico de cancer usando inmunomeros junto con agentes quimioterapeuticos.
CY1108629T1 (el) Συνδυασμος ετ 743 με 5 φθοριοουρακιλο προ-φαρμακα δια την θεραπευτικη αγωγη του καρκικου
CY2008007I2 (el) Χρηση του et743 στην συνδυαστικη θεραπεια με δεξαμεθαζονη για την θεραπευτικη αγωγη του καρκινου
PT1244650E (pt) Derivados arilaminas e sua aplicacao como agentes anti-telomerase
NO20032027L (no) Effektive antitumorbehandlinger
EP1605847A4 (en) Antibody-targeted photodynamic therapy
MX2007006557A (es) Metodos para utilizar intratecalmente una formulacion de temozolomida en el tratamiento de canceres.
MXPA04005207A (es) Metodos para tratar cancer utilizando un inhibidor de la farnesil proteina transferasa y agentes antineoplasticos.
MXPA05009849A (es) Terapia combinada que comprende nemorubicina y un inhibidor de la ciclooxigenasa-2.
BR0308976A (pt) Terapia combinada contra tumores compreendendo derivados de acriloil distamicina substituìda e radioterapia
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
WO2006069217A3 (en) Small molecule cyclin d1 ablative agents
BRPI0409870A (pt) uso de irinotecano para tratamento de cáncer de mama resistente
TW200509922A (en) Methods of therapeutic treatment using amounts of retinoid components
UA36920A (uk) Спосіб лікування хронічного катарального гінгівіту у дітей
MX2007000263A (es) Tratamiento de cancer.
TNSN06454A1 (en) Treatment of cancer
ITMI20001378A0 (it) Uso della nimesulide nel trattamento di patologie dermatologiche
ECSP993003A (es) Uso de peg - ifn -alpha y ribavirina para el tratamiento de hepatitis c cronica